Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of “Hold” from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been given a consensus rating of “Hold” by the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $29.15.

A number of brokerages recently issued reports on CAPR. Roth Capital cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective on the stock. in a research note on Monday, July 27th. Cantor Fitzgerald raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday. Maxim Group cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Oppenheimer restated a “market perform” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Finally, JonesTrading downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st.

Insider Buying and Selling at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 25,000 shares of company stock valued at $759,158. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 557 shares during the last quarter. KBC Group NV purchased a new stake in Capricor Therapeutics in the first quarter worth about $44,000. ACT Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth about $43,000. Nuveen LLC boosted its position in Capricor Therapeutics by 2.1% during the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock valued at $2,625,000 after acquiring an additional 1,878 shares in the last quarter. Finally, State of Wyoming boosted its position in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Stock Performance

CAPR opened at $7.45 on Tuesday. Capricor Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $40.37. The firm has a 50-day moving average of $17.81 and a 200 day moving average of $25.28. The firm has a market cap of $431.43 million, a P/E ratio of -3.04 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Friday, August 14th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Equities research analysts predict that Capricor Therapeutics will post -1.62 earnings per share for the current fiscal year.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor shares recently rallied after CEO comments addressing scrutiny of deramiocel and its regulatory outlook helped restore some investor confidence. The rebound may also have attracted short covering and speculative buying. Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
• Neutral Sentiment: Multiple law firms reiterated that investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, may seek lead-plaintiff status in a securities class action. The stated deadline is generally September 28, 2026, although one notice cites September 29. These announcements largely repeat existing litigation information rather than represent a new court ruling. Deadline Alert: Capricor Therapeutics Shareholders
• Negative Sentiment: The litigation notices allege that Capricor and certain executives made material misstatements or omissions concerning the statistical analysis plan, FDA compliance, and clinical prospects for its lead candidates. One notice links the allegations to an approximately $15.08 per-share decline following FDA briefing documents on the HOPE-3 trial, while another characterizes the prior decline as roughly 64%. The allegations have not been proven in court. CAPR Investor Alert: Securities Class Action Notice
• Negative Sentiment: Capricor’s recent quarterly loss exceeded analyst expectations, adding pressure to a stock whose valuation depends heavily on successful clinical development and regulatory progress. The repeated securities-fraud announcements increase reputational, legal, and uncertainty risks even as the shares remain well below their longer-term moving averages.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.